Selected article for: "lobe involvement and multiple lobe involvement"
Author: Wang, Yu; Li, Lan; Pan, Yuanjiang; He, Yu; Chen, Zuhua; Xun, Yunhao; Xu, Yuhan; Guo, Yilei; Yang, Jiehong; Guo, Jianchun; Wan, Haitong
Title: Comparison of the clinical features and therapeutics of COVID-19 in cardio-cerebrovascular disease (CCVD) and non-CCVD patients
  • Cord-id: ckrcxz6f
  • Document date: 2021_4_28
    • ID: ckrcxz6f
    Snippet: Cardio-cerebrovascular disease (CCVD) is a major comorbidity of Coronavirus disease 2019 (COVID-19). However, the clinical characteristics and outcomes remain unclear. In this study, 102 cases of COVID-19 from January 22, 2020 to March 26, 2020 in Xixi Hospital of Hangzhou were included. Twenty cases had pre-existing CCVD. Results showed that compared with non-CCVD patients, those with CCVD are more likely to develop severe disease (15% versus 1%), and the proportion of pneumonia severity index
    Document: Cardio-cerebrovascular disease (CCVD) is a major comorbidity of Coronavirus disease 2019 (COVID-19). However, the clinical characteristics and outcomes remain unclear. In this study, 102 cases of COVID-19 from January 22, 2020 to March 26, 2020 in Xixi Hospital of Hangzhou were included. Twenty cases had pre-existing CCVD. Results showed that compared with non-CCVD patients, those with CCVD are more likely to develop severe disease (15% versus 1%), and the proportion of pneumonia severity index grade IV was significantly higher (25% versus 3.6%). Computed tomography images demonstrated that the proportion of multiple lobe lesion involvement was significantly higher in the CCVD group than in the non-CCVD group (90% versus 63.4%). Compared with non-CCVD group, the levels of C-reactive protein, fibrinogen, D-dimer, and serum amyloid-A were higher, whereas the total protein and arterial partial PaO(2) were lower in the CCVD group. Although no statistical difference was observed in the outcomes between groups, CCVD patients received more intensive comprehensive treatment to improve COVID-19 symptoms compared with non-CCVD patients. Integrated Chinese and Western medicine treatments have certain advantages in controlling the severe conversion rate and mortality of COVID-19. In addition, given that COVID-19 patients are usually related to coagulation disorders and thrombosis risk, the application of Chinese medicine in promoting blood circulation and removing stasis should be strengthened.

    Search related documents:
    Co phrase search for related documents
    • abdominal distension and acute respiratory distress syndrome: 1
    • absence presence and acid testing: 1
    • absence presence and acute phase: 1, 2, 3, 4, 5, 6, 7, 8
    • absence presence and acute pulmonary embolism: 1, 2, 3, 4, 5
    • absence presence and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • absence presence and admission patient: 1
    • absence presence and liver renal: 1, 2
    • acid testing and acute phase: 1, 2, 3
    • acid testing and acute respiratory distress syndrome: 1
    • acid testing and admission patient: 1, 2, 3, 4
    • acid testing and liver renal: 1
    • acute phase and admission patient: 1, 2, 3
    • acute phase and liver renal: 1, 2, 3
    • acute phase and liver renal function: 1
    • acute pulmonary embolism and admission patient: 1, 2
    • acute respiratory distress syndrome and admission patient: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and liver renal: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute respiratory distress syndrome and liver renal function: 1, 2, 3
    • admission patient and liver renal: 1, 2, 3, 4